| # | Title | Journal | Year | Citations |
|---|
| 1 | Salvage Stereotactic Body Radiotherapy for Patients With Limited Prostate Cancer Metastases: Deferring Androgen Deprivation Therapy | Clinical Genitourinary Cancer | 2013 | 169 |
| 2 | Potential Histologic and Molecular Predictors of Response to Temsirolimus in Patients with Advanced Renal Cell Carcinoma | Clinical Genitourinary Cancer | 2007 | 168 |
| 3 | Phase I Study Combining Treatment with Temsirolimus and Sunitinib Malate in Patients with Advanced Renal Cell Carcinoma | Clinical Genitourinary Cancer | 2009 | 148 |
| 4 | A Phase II Study of Depsipeptide in Refractory Metastatic Renal Cell Cancer | Clinical Genitourinary Cancer | 2006 | 140 |
| 5 | Expression of microRNAs in the Urine of Patients With Bladder Cancer | Clinical Genitourinary Cancer | 2012 | 134 |
| 6 | Results of a Prospective Phase 2 Pilot Trial of 177Lu–PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression | Clinical Genitourinary Cancer | 2019 | 131 |
| 7 | Trends in Renal-Cell Carcinoma Incidence and Mortality in the United States in the Last 2 Decades: A SEER-Based Study | Clinical Genitourinary Cancer | 2019 | 130 |
| 8 | Comparison of Circulating MicroRNA 141 to Circulating Tumor Cells, Lactate Dehydrogenase, and Prostate-Specific Antigen for Determining Treatment Response in Patients With Metastatic Prostate Cancer | Clinical Genitourinary Cancer | 2011 | 124 |
| 9 | The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer | Clinical Genitourinary Cancer | 2018 | 115 |
| 10 | Cutaneous Squamous Cell Carcinoma and Inflammation of Actinic Keratoses Associated with Sorafenib | Clinical Genitourinary Cancer | 2009 | 103 |
| 11 | The Effect of Zoledronic Acid on Bone Mineral Density in Patients Undergoing Androgen Deprivation Therapy | Clinical Genitourinary Cancer | 2007 | 102 |
| 12 | Two-Year Survival Follow-Up of the Randomized, Double-Blind, Placebo-Controlled Phase II Study of Radium-223 Chloride in Patients With Castration-Resistant Prostate Cancer and Bone Metastases | Clinical Genitourinary Cancer | 2013 | 98 |
| 13 | Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States | Clinical Genitourinary Cancer | 2020 | 91 |
| 14 | 68Ga-PSMA PET/CT Replacing Bone Scan in the Initial Staging of Skeletal Metastasis in Prostate Cancer: A Fait Accompli? | Clinical Genitourinary Cancer | 2018 | 88 |
| 15 | Risk of Hand-Foot Skin Reaction with the Multitargeted Kinase Inhibitor Sunitinib in Patients with Renal Cell and Non–Renal Cell Carcinoma: A Meta-analysis | Clinical Genitourinary Cancer | 2009 | 86 |
| 16 | The AKT Inhibitor Perifosine in Biochemically Recurrent Prostate Cancer: A Phase II California/Pittsburgh Cancer Consortium Trial | Clinical Genitourinary Cancer | 2007 | 85 |
| 17 | Circulating Tumor Cells as a Predictive Biomarker in Patients With Hormone-sensitive Prostate Cancer | Clinical Genitourinary Cancer | 2011 | 85 |
| 18 | Radical Prostatectomy or Radiotherapy in High-Risk Prostate Cancer: A Systematic Review and Metaanalysis | Clinical Genitourinary Cancer | 2014 | 85 |
| 19 | The Clinical Use of the Neutrophil to Lymphocyte Ratio (NLR) in Urothelial Cancer: A Systematic Review | Clinical Genitourinary Cancer | 2016 | 84 |
| 20 | Sacituzumab Govitecan, a Novel Antibody–Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma | Clinical Genitourinary Cancer | 2016 | 80 |
| 21 | Transperineal Versus Transrectal MRI/TRUS Fusion Targeted Biopsy: Detection Rate of Clinically Significant Prostate Cancer | Clinical Genitourinary Cancer | 2017 | 80 |
| 22 | Positive Surgical Margins After Nephron-Sparing Surgery for Renal Cell Carcinoma: Incidence, Clinical Impact, and Management | Clinical Genitourinary Cancer | 2013 | 79 |
| 23 | Predicting Time From Metastasis to Overall Survival in Castration-Resistant Prostate Cancer: Results From SEARCH | Clinical Genitourinary Cancer | 2017 | 79 |
| 24 | Gemcitabine, Cisplatin, and Sunitinib for Metastatic Urothelial Carcinoma and as Preoperative Therapy for Muscle-Invasive Bladder Cancer | Clinical Genitourinary Cancer | 2013 | 78 |
| 25 | Outcome of Patients With Metastatic Sarcomatoid Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium | Clinical Genitourinary Cancer | 2015 | 78 |
| 26 | Hypoxia and Prostate Cancer Aggressiveness: A Tale With Many Endings | Clinical Genitourinary Cancer | 2015 | 76 |
| 27 | Perioperative Complications and Mortality After Radical Cystectomy When Using a Standardized Reporting Methodology | Clinical Genitourinary Cancer | 2013 | 75 |
| 28 | Hematologic Safety of Radium-223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial | Clinical Genitourinary Cancer | 2017 | 75 |
| 29 | Phase II Evaluations of Cilengitide in Asymptomatic Patients with Androgen-Independent Prostate Cancer: Scientific Rationale and Study Design | Clinical Genitourinary Cancer | 2006 | 73 |
| 30 | Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab | Clinical Genitourinary Cancer | 2018 | 72 |
| 31 | Treatment of Advanced Renal Cell Carcinoma with the Combination Bevacizumab/Erlotinib/Imatinib: A Phase I/II Trial | Clinical Genitourinary Cancer | 2007 | 71 |
| 32 | Salvage Stereotactic Body Radiotherapy for Isolated Lymph Node Recurrent Prostate Cancer: Single Institution Series of 94 Consecutive Patients and 124 Lymph Nodes | Clinical Genitourinary Cancer | 2017 | 71 |
| 33 | Discovery of Potential Bladder Cancer Biomarkers by Comparative Urine Proteomics and Analysis | Clinical Genitourinary Cancer | 2013 | 70 |
| 34 | Sarcopenia Evaluated Using the Skeletal Muscle Index Is a Significant Prognostic Factor for Metastatic Urothelial Carcinoma | Clinical Genitourinary Cancer | 2016 | 69 |
| 35 | 18F-FACBC Compared With 11C-Choline PET/CT in Patients With Biochemical Relapse After Radical Prostatectomy: A Prospective Study in 28 Patients | Clinical Genitourinary Cancer | 2014 | 68 |
| 36 | A Phase II Trial of Sunitinib in Patients With Renal Cell Cancer and Untreated Brain Metastases | Clinical Genitourinary Cancer | 2014 | 66 |
| 37 | Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: A Systematic Review With a Meta-Analysis | Clinical Genitourinary Cancer | 2016 | 66 |
| 38 | Spontaneous Regression of Thoracic Metastases While Progression of Brain Metastases After Stereotactic Radiosurgery and Stereotactic Body Radiotherapy for Metastatic Renal Cell Carcinoma: Abscopal Effect Prevented by the Blood-Brain Barrier? | Clinical Genitourinary Cancer | 2012 | 65 |
| 39 | Luteinizing Hormone–Releasing Hormone Agonists: A Quick Reference for Prevalence Rates of Potential Adverse Effects | Clinical Genitourinary Cancer | 2013 | 65 |
| 40 | Prognostic Factors of Survival for Patients With Metastatic Renal Cell Carcinoma With Brain Metastases Treated With Targeted Therapy: Results From the International Metastatic Renal Cell Carcinoma Database Consortium | Clinical Genitourinary Cancer | 2013 | 64 |
| 41 | A Systematic Review and Meta-analysis of the Diagnostic Accuracy of Prostate Health Index and 4-Kallikrein Panel Score in Predicting Overall and High-grade Prostate Cancer | Clinical Genitourinary Cancer | 2017 | 64 |
| 42 | High Expression of Long Noncoding RNA MALAT1 Indicates a Poor Prognosis and Promotes Clinical Progression and Metastasis in Bladder Cancer | Clinical Genitourinary Cancer | 2017 | 64 |
| 43 | Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer | Clinical Genitourinary Cancer | 2018 | 64 |
| 44 | Inhibition of DNA Methylation by Antisense Oligonucleotide MG98 as Cancer Therapy | Clinical Genitourinary Cancer | 2007 | 63 |
| 45 | Phase I/II Study of Azacitidine, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Therapy | Clinical Genitourinary Cancer | 2015 | 63 |
| 46 | Assessment of Sunitinib-Induced Toxicities and Clinical Outcomes Based on Therapeutic Drug Monitoring of Sunitinib for Patients With Renal Cell Carcinoma | Clinical Genitourinary Cancer | 2015 | 63 |
| 47 | Phase I Trial of Sunitinib Malate plus Interferon-α for Patients with Metastatic Renal Cell Carcinoma | Clinical Genitourinary Cancer | 2009 | 62 |
| 48 | PSA Flare With Abiraterone in Patients With Metastatic Castration-Resistant Prostate Cancer | Clinical Genitourinary Cancer | 2015 | 62 |
| 49 | Stromal-Epithelial Interaction in Prostate Cancer Progression | Clinical Genitourinary Cancer | 2006 | 61 |
| 50 | Preoperative Neutrophil-Lymphocyte Ratio as an Independent Prognostic Marker for Patients With Upper Urinary Tract Urothelial Carcinoma | Clinical Genitourinary Cancer | 2013 | 61 |
